Abich Financial Wealth Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Abich Financial Wealth Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$80.1K	Buy	+9,214	New	+$55.1K	0.03%	261

Other funds holding FDMT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Abich Financial Wealth Management's FDMT Position: Q3 2025 in Review

Abich Financial Wealth Management opened a new position in 4D Molecular Therapeutics (FDMT) in Q3 2025: 9,214 shares worth $80.1K. The stake represents 0.03% of the portfolio and ranks #261 among its holdings.

134 funds tracked by Wall St. Rank hold FDMT as of Q3 2025.

Abich Financial Wealth Management held 9,214 shares of 4D Molecular Therapeutics worth $80.1K as of Q3 2025.
4D Molecular Therapeutics was a new Abich Financial Wealth Management position in Q3 2025.
4D Molecular Therapeutics made up 0.03% of Abich Financial Wealth Management's portfolio in Q3 2025, its #261 holding.
134 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2025.

Based on Abich Financial Wealth Management's 13F filing for Q3 2025, filed 6 Nov 2025.